Overview: Galactosemia 1 Panel
Introduction: The Galactosemia 1 Panel is a diagnostic tool designed to screen for galactosemia variants using whole blood samples. In India, galactosemia variants (GALT, GALE, GALK1 deficiencies) present with neonatal jaundice, vomiting, or later cataracts/cognitive issues, with compound heterozygosity common. High morbidity from underdiagnosis in rural/low-SES neonates, limited genetic labs, delayed lactose-free diet leading to irreversible damage. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for GALT, GALE, GALK1 mutations over 1-2 days with high accuracy, valuable for variant identification in suspected cases. This diagnostic falls under genetic disorder screening and targets neonates with feeding intolerance or family history, addressing accurate detection to guide dietary management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise variant confirmation and reducing complications. Its whole blood-based approach ensures reliable mutation analysis.
Other Names: Galacto 1 Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.
Historical Milestone: Multi-gene galactosemia panel; in India, expanding in metabolic screening.
Purpose: The test assesses 3 parameters including GALT mutation to guide galactosemia variant screening, detect deficiencies, inform diet.
Test Parameters: 1. GALT Mutation, 2. GALE Mutation, 3. GALK1 Mutation.
Pretest Condition: No fasting required; patients should be symptomatic neonates.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on jaundice, vomiting, family history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated galactosemia including damage, benefits of early detection, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Pathogenic variants confirm galactosemia, necessitating specialist input. Normal may require follow-up.
Specialist Consultation: Pediatricians or geneticists should be consulted for management.
Additional Supporting Tests: Enzyme activity, galactose levels for confirmation.
Test Limitations: Detects common variants; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023.
